Enhanced synthesis of cysteinyl leukotrienes in psoriasis.
Cysteinyl leukotriene synthesis was investigated in patients with psoriasis. A non-invasive test requiring no stimulation was employed by measuring the major index metabolite of LTC4, which appears in urine. The presence of this metabolite, LTE4, was shown unequivocally by gas chromatography-mass spectrometry. Routinely LTE4 was quantitated by specific radio immunoassay after its isolation by reversed-phase high-performance liquid chromatography. Furthermore, in representative samples amounts of LTE4 obtained by radioimmunoassay were validated by gas chromatography-mass spectrometry. We demonstrate a significant (p less than 0.01) more than fourfold increase of urinary LTE4 in psoriasis compared to healthy volunteers. Urinary LTE4 was log normally distributed with geometric mean values (95% confidence intervals) of 11 (9-14) nmol LTE4/mol creatinine in healthy volunteers (n = 11) and 51 (28-95) nmol LTE4/mol creatinine in psoriasis (n = 9). The present study shows that cysteinyl leukotriene synthesis is enhanced in patients with psoriasis and that measurement of urinary LTE4 is a useful parameter to monitor its rate of synthesis.
Fauler
J
J
Department of Clinical Pharmacology, Hannover Medical School, Germany.
Neumann
C
C
Tsikas
D
D
Frölich
J
J
D000328:Adult; D002940:Circadian Rhythm; D005260:Female; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D017999:Leukotriene E4; D008297:Male; D011565:Psoriasis / Q000378:metabolism*; D011863:Radioimmunoassay; D013189:SRS-A / Q000031:analogs & derivatives* / Q000096:biosynthesis* / Q000652:urine
D013189:SRS-A; D017999:Leukotriene E4